Dew, would you be adding IDIX more at these price levels?
I’ve added modestly since the GSK deal was announced.
IDIX’s high volatility can definitely be used to advantage—in 2008, this was a significant factor in my achieving a 54% overall return in my biotech portfolio (#msg-34511933). Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”